Discovery and characterization of benzyloxy piperidine based dopamine 4 receptor antagonists

22 September 2021, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Abstract: The dopamine receptor 4 (D4R) is highly expressed in both motor, associative and limbic subdivisions of the coritico-basal ganglia network. Due to the distribution in the brain, there is mounting evidence pointing to a role for the D4R in the modulation of this network and its subsequent involvement in L-DOPA induced dyskinesias in Parkinson’s disease. As part of our continued effort in the discovery of novel D4R antagonists, we report the discovery and characterization of a new 3- or 4-benzyloxypiperidine scaffold as D4R antagonists. We report several D4R selective compounds (>30-fold vs. other dopamine receptor subtypes) with improved in vitro and in vivo stability over previously reported D4R antagonists.

Keywords

Dopamine 4 receptor
D4R antagonists
benzyloxypiperidine
Parkinson's disease

Supplementary materials

Title
Description
Actions
Title
Chemical synthesis and characterization of D4 antagonists
Description
Chemical synthesis and characterization
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.